BACKGROUND:Ezetimibe inhibits intestinal absorption of cholesterol. METHODS: Multicentered double-blind, randomized, placebo-controlled, crossover study to determine the short-term safety, efficacy, and tolerability of ezetimibe in combination with ongoing statin therapy in HIV-infected adults with elevated low-density lipoprotein cholesterol (LDL-C). Participants on stable HAART with fasting LDL-C at least 130 mg/dl and stable statin were randomized to ezetimibe 10 mg daily or placebo for 12 weeks followed by 4 weeks of washout and then 12 weeks with alternative study assignment. Percentage and absolute change in LDL-C (primary endpoint), total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), apolipoprotein B, and high sensitivity C-reactive protein were compared. Changes in clinical symptoms and safety laboratory measurements were assessed. RESULTS:Forty-four participants enrolled: 70% men, median age 49 years, 43% White/Non-Hispanic, median CD4 cell count 547 cells/microl, and 95% HIV RNA less than 50 copies/ml. Median (interquartile range) percentage change in LDL-C was -20.8% (-25.4, -10.7) with ezetimibe and -0.7% (-10.3,18.6) with placebo; the median within-participant effect of ezetimibe was -14.1% (-33.0, -5.0; P < 0.0001). Median difference in absolute LDL-C values between ezetimibe and placebo was -32 mg/dl (-58, -6, P < 0.0001). Significant differences in within-participant effect of ezetimibe were noted for total cholesterol -18.60% (-27.22, -11.67, P < 0.001), non-HDL-C -23.18% (-33.14, -14.36, P < 0.0001), and apolipoprotein B -8.73% (-18.75, 1.99, P = 0.02). No significant changes seen in HDL-C, triglyceride, or high sensitivity C-reactive protein. Ezetimibe was well tolerated. Adverse events were similar between phases. CONCLUSION: The present short-term study found adding ezetimibe to ongoing statin therapy was well tolerated and effective in reducing LDL-C, total cholesterol, non-HDL-C, and apolipoprotein B. Adding ezetimibe to statin therapy offers reasonable treatment option for HIV-infected patients with elevated LDL-C.
RCT Entities:
BACKGROUND:Ezetimibe inhibits intestinal absorption of cholesterol. METHODS: Multicentered double-blind, randomized, placebo-controlled, crossover study to determine the short-term safety, efficacy, and tolerability of ezetimibe in combination with ongoing statin therapy in HIV-infected adults with elevated low-density lipoprotein cholesterol (LDL-C). Participants on stable HAART with fasting LDL-C at least 130 mg/dl and stable statin were randomized to ezetimibe 10 mg daily or placebo for 12 weeks followed by 4 weeks of washout and then 12 weeks with alternative study assignment. Percentage and absolute change in LDL-C (primary endpoint), total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), apolipoprotein B, and high sensitivity C-reactive protein were compared. Changes in clinical symptoms and safety laboratory measurements were assessed. RESULTS: Forty-four participants enrolled: 70% men, median age 49 years, 43% White/Non-Hispanic, median CD4 cell count 547 cells/microl, and 95% HIV RNA less than 50 copies/ml. Median (interquartile range) percentage change in LDL-C was -20.8% (-25.4, -10.7) with ezetimibe and -0.7% (-10.3,18.6) with placebo; the median within-participant effect of ezetimibe was -14.1% (-33.0, -5.0; P < 0.0001). Median difference in absolute LDL-C values between ezetimibe and placebo was -32 mg/dl (-58, -6, P < 0.0001). Significant differences in within-participant effect of ezetimibe were noted for total cholesterol -18.60% (-27.22, -11.67, P < 0.001), non-HDL-C -23.18% (-33.14, -14.36, P < 0.0001), and apolipoprotein B -8.73% (-18.75, 1.99, P = 0.02). No significant changes seen in HDL-C, triglyceride, or high sensitivity C-reactive protein. Ezetimibe was well tolerated. Adverse events were similar between phases. CONCLUSION: The present short-term study found adding ezetimibe to ongoing statin therapy was well tolerated and effective in reducing LDL-C, total cholesterol, non-HDL-C, and apolipoprotein B. Adding ezetimibe to statin therapy offers reasonable treatment option for HIV-infectedpatients with elevated LDL-C.
Authors: Scott E Conard; Harold E Bays; Lawrence A Leiter; Steven R Bird; Joseph Rubino; Robert S Lowe; Joanne E Tomassini; Andrew M Tershakovec Journal: Am J Cardiol Date: 2008-10-23 Impact factor: 2.778
Authors: Lawrence A Leiter; Harold Bays; Scott Conard; Steven Bird; Joseph Rubino; Mary E Hanson; Joanne E Tomassini; Andrew M Tershakovec Journal: Am J Cardiol Date: 2008-10-23 Impact factor: 2.778
Authors: Judith A Aberg; Robert A Zackin; Susan W Brobst; Scott R Evans; Beverly L Alston; W Keith Henry; Marshall J Glesby; Francesca J Torriani; Yijun Yang; Susan I Owens; Carl J Fichtenbaum Journal: AIDS Res Hum Retroviruses Date: 2005-09 Impact factor: 2.205
Authors: Anne B Rossebø; Terje R Pedersen; Kurt Boman; Philippe Brudi; John B Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph A Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer Journal: N Engl J Med Date: 2008-09-02 Impact factor: 91.245
Authors: Jerome L Fleg; Mihriye Mete; Barbara V Howard; Jason G Umans; Mary J Roman; Robert E Ratner; Angela Silverman; James M Galloway; Jeffrey A Henderson; Matthew R Weir; Charlton Wilson; Mario Stylianou; Wm James Howard Journal: J Am Coll Cardiol Date: 2008-12-16 Impact factor: 24.094
Authors: John J P Kastelein; Fatima Akdim; Erik S G Stroes; Aeilko H Zwinderman; Michiel L Bots; Anton F H Stalenhoef; Frank L J Visseren; Eric J G Sijbrands; Mieke D Trip; Evan A Stein; Daniel Gaudet; Raphael Duivenvoorden; Enrico P Veltri; A David Marais; Eric de Groot Journal: N Engl J Med Date: 2008-03-30 Impact factor: 91.245
Authors: S Oswald; H E Meyer zu Schwabedissen; A Nassif; C Modess; Z Desta; E T Ogburn; J Mostertz; M Keiser; J Jia; A Hubeny; A Ulrich; D Runge; M Marinova; D Lütjohann; H K Kroemer; W Siegmund Journal: Clin Pharmacol Ther Date: 2012-02-01 Impact factor: 6.875